Your search
In authors or contributors
Results 2 resources
-
Background. Neutropenia may limit use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy of maribavir with fewer treatment-limiting toxicities than valganciclovir. Methods. In this multicenter, double-blind, phase 3 study, patients with first asymptomatic CMV infection post-HCT were stratified and randomized 1:1 to maribavir 400 mg twice daily or valganciclovir (dose-adjusted for renal clearance)...
Last update from database: 4/26/26, 2:00 AM (EST)
Filter by our tag
ORGANISMS
-
VIRUSES
(2)
-
CMV
(2)
- Letermovir (1)
- Maribavir (1)
-
CMV
(2)
HEME-ONC AND CELLULAR THERAPIES
- BMT-specific ID (1)
- Heme-onc prophylaxis (1)
ARTICLE OF THE MONTH
- 2023 (1)
ATC 2024 Top Papers in TID
- VIRUSES (1)